CA-ARMIS
12.2.2024 14:01:29 CET | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced that it has been named a Top Performer in the 2024 Best in KLAS Software & Services Report for Healthcare IoT Security for the second year in a row. The Best in KLAS report recognizes software and services companies that excel in helping healthcare professionals improve patient care.
“This recognition from KLAS which is based solely on customer reviews is a true testament to our ongoing commitment to protecting the attack surfaces of healthcare organizations,” said Mohammad Waqas, CTO of Healthcare at Armis. “I want to thank every Armis customer who took the time this year to share with KLAS their experience with Armis CentrixTM for Medical Device Security. Your feedback is instrumental in helping us continuously improve our solutions and deliver the best possible value to the healthcare community.”
The 2024 Best in KLAS report, based on independent feedback from healthcare providers in North America, evaluates vendors across six key performance areas: culture, loyalty, operations, product, relationship and value. Armis achieved an outstanding overall score, demonstrating excellence in every category and solidifying the company’s position as a leader in Healthcare IoT Security.
When asked about Armis, customers shared the following anonymized comments with KLAS in review of the company’s solution:
- “Given the nature of how sensitive and aware we have all become to some of the hazards surrounding cybersecurity and cyber risks associated with penetration into personal health information through many different avenues of medical devices and applications, the Armis application is robust in being able to see all network-connected devices. It is really incredible to see the amount of horsepower that the Armis platform brings to the table for us. The product really is a great tool. Not only can the reporting piece identify connected devices but it is able to identify what type of device something is through the product's algorithms. The product is able to determine what the make, model, and serial number are, and in some cases, what operating system the device is functioning on. Recently, we had an issue with updating the security on anything that was still running on something other than Windows 10, and through the Armis system, we were able to see how many devices were reporting through the application that were not up to Windows 10. With the reporting structure, we now have a line of sight into many things we didn't know about.” - Director, April 2023
- “Armis does very well with implementations. They are very knowledgeable about their products. They have experts on their team, so if we need some help with a configuration, they have resources available that are on standby typically to help and engage in troubleshooting.” - Analyst/Coordinator, April 2023
- “In general, Armis regularly updates their platform and gives good notifications about new enhancements and new features. They back those notifications up with written material and videos, as well as live sessions if we are lucky enough to find the time to attend them. It is good that the vendor is constantly adding new features and new capabilities to the product.” - Analyst/Coordinator, September 2023
In July 2023, Armis was rated the best-performing cross-industry vendor in the KLAS Healthcare IoT Security 2023 report for its deep coverage of IoT, OT, IoMT and IT across all verticals.
In the past year, Armis has continued to deepen its commitment to securing healthcare organizations. Combining the power of Armis CentrixTM, the cyber exposure management platform, and the Armis AI-powered Asset Intelligence Engine, Armis has reinforced its healthcare-specific capabilities which help to provide complete visibility and security for all medical devices, clinical assets and the entire healthcare ecosystem with zero disruptions to patient care.
Armis is a sponsor of HIMSS 2024, taking place in Orlando, FL March 11-15. Stop by Armis’ booth #1621 in the CyberSecurity Command Center or visit the team in the Main Walkway at booth #1048. At HIMSS, Armis’ CTO of Healthcare, Mohammad Waqas, will speak to “Building a Comprehensive Healthcare Security Program for Next-Gen Patient Care.” This session will be held on Tuesday, March 12th from 10:15am - 10:30am EDT in the Orange County Convention Center, Theatre A.
To read the KLAS report, please visit: 2024 Best in KLAS - Software & Services
To learn more about Armis CentrixTM for Medical Device Security, go to: https://www.armis.com/platform/armis-centrix-for-medical-device-security/
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
About KLAS Research
KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212843101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 09:00:00 CEST | Press release
Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 09:00:00 CEST | Press release
Partnership aims to reduce the ‘meeting tax’ by expanding access to Owl Labs products through Westcoast’s extensive distribution network Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and s
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 09:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 08:00:00 CEST | Press release
The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled
Vedanta FY26 Profit Soars by 22% to $2.8 bn; Enters Demerger Phase11.5.2026 02:30:00 CEST | Press release
India-based Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals, oil & gas, critical minerals, power and technology, announced its results for the fourth quarter and full year ended 31 March 2026. It has delivered its best-ever financial performance, driven by structurally strong businesses and disciplined execution. For the full year, Vedanta’s Profit stood at an all-time high of $2.8 bn, reflecting a 22% YoY increase and a profit of $1 bn in Q4 FY26, up nearly 90% YoY. Vedanta reported its highest-ever annual revenue of about $20 bn, up 15% YoY, with Q4 revenue at $5.6 bn, an increase of nearly 30% YoY. The Company maintained strong cost leadership, contributing to record EBITDA of $6.3 bn for FY26, up by about 30% YoY, with margins expanding to around 40%. Q4 EBITDA stood at $2.0 bn, up by nearly 60% YoY, with a margin of approximately 44%. The balance sheet strengthened further, with Net Debt/EBITDA improving to 0.95x, supported by strong cash generation. Underscor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
